生物分析
多学科方法
背景(考古学)
工程伦理学
透视图(图形)
纳米技术
计算机科学
化学
数据科学
基石
监管科学
管理科学
知识库
多样性(控制论)
工程类
代理(哲学)
生化工程
科学哲学
作者
Federico Riccardi Sirtori,Robert Wheller,Jordane Biarc,Christoph Bock,Charlie Britten,Lisa Dietz,Fabrizia Fusetti,Fabian Gaertner,Benno A. Ingelse,Robert J. Nelson,Bodrul Noor,Rebecca Paterson,Jörg Pausch,Vincenzo Pucci,Marie Rossen,Leroy Schreuder,Daniel Schulz-Jander,Craig Stovold,Helena Vostiarova,Philip Timmerman
出处
期刊:Bioanalysis
[Future Science Ltd]
日期:2026-11-06
卷期号:: 1-6
标识
DOI:10.1080/17576180.2026.2753698
摘要
Antibody–drug conjugates are a highly complex therapeutic modality that challenge conventional bioanalytical paradigms. Following a multidisciplinary workshop, the European Bioanalysis Forum developed a strategic perspective on how bioanalysis should evolve to support contemporary and future antibody–drug conjugates development. Central to this perspective is the recognition that antibody–drug conjugates are heterogeneous and dynamically changing therapeutic entities whose composition can be modified in vivo through processes such as deconjugation, payload release, linker cleavage, biotransformation and changes in DAR distribution, requiring bioanalysis to move beyond individual analyte measurements toward integrated biological understanding. The European Bioanalysis Forum proposes that bioanalytical strategies should be driven by clearly defined scientific questions and Context of Use, substantiated with additional complementary analytical approaches selected to generate evidence that supports development decisions. Rather than providing prescriptive methodological recommendations, this paper presents a flexible scientific framework that integrates multidisciplinary expertise and encourages continued scientific dialogue and publication of case studies to strengthen the evidence base as antibody–drug conjugates science continues to evolve.
科研通智能强力驱动
Strongly Powered by AbleSci AI